IOVA · Iovance Biotherapeutics Inc
Price
Snapshot
50 fields · last close| Market Cap | $6.17B |
| P/E | — |
| Float | 416.0M |
| Beta | 0.77 |
| Volatility | 19.2% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Moderate |
| Clavix score | 38.9 |
| Price | 14.28 |
| Change | +4.85% |
| Prev Close | 13.62 |
| Open | 14.65 |
| Day Low | 13.52 |
| Day High | 14.71 |
| Avg Vol | 13 |
| Avg $ Vol | $180.3M |
| 52W High | 15.30 |
| 52W Low | 1.76 |
| 52W Pos | 92.5% |
| From High | −6.67% |
| From Low | +711.36% |
| Max DD 1Y | −39.00% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +9.39% |
| SMA 50 | +41.11% |
| SMA 200 | +169.59% |
| RSI (14) | 59.9 |
| Vol 30D | 101.2% |
| Vol 90D | 106.9% |
| 1Y Range | 2–15 |
| Daily bars | 536 |
| Perf Week | −6.84% |
| Perf Month | +35.93% |
| Perf Quarter | +171.31% |
| Perf Half Y | +252.85% |
| Perf Year | +508.04% |
| Perf YTD | +466.67% |
| Prev Day | +4.85% |
| Clavix | D- |
| Debt / Eq | 0.00 |
| Curr Ratio | 3.20 |
| Int Cover | -0.6× |
| FCF Margin | — |
| Rev Growth | +60.6% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 31 / 35 |
Clavix risk grade
regraded every trading dayIOVA grades D-, 38.9 of 100. Steadiest on News Sentiment (68), most exposed on Price Stability (6, weak). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 31 of 35 in Biotechnology by Clavix score.
How rough the ride is
| IOVA | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.77 | 0.51 |
| Volatilityannualized | 19.2% | 14.6% |
| Max drawdown, past yearworst peak-to-trough fall | −39.0% | — |
| Typical daily movemedian absolute daily change | 2.86% | — |
| Days beyond ±3%of the last 252 sessions | 123 (49%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| IOVA | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.77 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| IOVA | |
|---|---|
| 1 week | −6.8% |
| 1 month | +35.9% |
| Year to date | +466.7% |
| 1 year | +508.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| IOVA | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 6 Aug |
| Average score0 most bearish, 100 most bullish | 76 |
| Bullish · bearisharticles above 60 · below 40 | 29 · 1 |
| Directionarticles whose tone is improving vs worsening | 29 ↑ 1 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| IOVA | |
|---|---|
| Revenue growthyear over year | +60.6% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openRobert W. Baird raised its price target on Iovance Biotherapeutics (IOVA) from $6.00 to $11.00 while keeping a "neutral" rating. The article body is cut off and does not explain the analyst's reasoning.
Iovance raised its 2026 revenue guidance to $410-$420 million, up from prior expectations, as sales of its Amtagvi cell therapy accelerate. The article outlines several growth drivers ahead, including expanded treatment access, faster manufacturing, and pipeline expansion into frontline melanoma, lung cancer, and international markets.
Iovance Biotherapeutics was the top-performing US mid-cap stock in the third quarter, with shares rising 256%, driven by strong demand for its cancer treatments. The company raised its full-year 2026 revenue growth guidance to 56-60% (a range of $410-420 million, up from $263 million in 2025), citing confidence in continued demand for its products Amtagvi and Proleukin.
This reflects the analyst's updated view, not a change at the company itself.
Iovance Biotherapeutics announced the appointment of Noah Berkowitz, M.D., Ph.D., as its new Chief Medical Officer, effective September 30, 2026. The article is truncated and does not include further details about his background or the company's stated reasons for the hire.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| IONS | Ionis Pharmaceuticals Inc | B- | $7.14B | — | 0.39 | Compare |
| CGON | CG Oncology Inc | B- | $5.31B | — | 0.31 | Compare |
| PTCT | PTC Therapeutics Inc | B | $4.94B | 7.24 | 0.51 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $7.90B | — | 1.36 | Compare |
| ERAS | Erasca Inc | C | $4.68B | — | 0.67 | Compare |
| TGTX | TG Therapeutics Inc | B- | $8.26B | 18.71 | 1.83 | Compare |
| PTGX | Protagonist Therapeutics Inc | B | $8.33B | 100.49 | 1.20 | Compare |
| CYTK | Cytokinetics Inc | B+ | $8.61B | — | 0.43 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.